ScholarIQanswers from OpenAlex & ORCID
Robert S. Mannel
ResearcherPublications, citations & collaboration network
Robert S. Mannel is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Robert S. Mannel have?
ScholarIQindexed works
Robert S. Mannel has 391 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert S. Mannel have?
ScholarIQcitation count
Robert S. Mannel has 51,813 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Robert S. Mannel?
ScholarIQh-index
Robert S. Mannel has an h-index of 83 in OpenAlex.
What is the i10-index of Robert S. Mannel?
ScholarIQi10-index
Robert S. Mannel has an i10-index of 192 in OpenAlex.
What is the OpenAlex record for Robert S. Mannel?
ScholarIQopenalex
The OpenAlex for Robert S. Mannel is on the source record.
What are the most-cited papers on Robert S. Mannel?
ScholarIQmost cited works
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel